×

Access Whitepaper

First Name
Last Name
Company
Thank you!
Error - something went wrong!
   

Ethical Biosafety Oversight of Gene Transfer Research

July 19, 2019

The number of drug products under development that incorporate recombinant or synthetic DNA or RNA, viral vectors, and/or genetically-modified organisms (“GMOs”) continues to grow rapidly, and several such products have received marketing approval from the FDA. This paper focuses on important points to consider when planning to initiate clinical trials with these products at sites inside or outside the USA, if the research is subject to rules and regulations of the FDA and/or the
National Institutes of Health (NIH) of the United States. In particular, we focus on the roles of Institutional Biosafety Committees (IBCs) and Institutional Review Boards (IRBs) in approving and facilitating study startup.

Previous Flipbook
WCG Playbook: Flipping the Funnel
WCG Playbook: Flipping the Funnel

Next Flipbook
The Most Important Voice Is Missing: The Case For Including Patient Insights In Protocol Design
The Most Important Voice Is Missing: The Case For Including Patient Insights In Protocol Design

Request a Genetics in Clinical Trials training session

What You'll Learn